Last update 24 Mar 2025

Ritonavir

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Ritonavir (JAN/USP/INN), RTV, A 84538
+ [11]
Action
inhibitors
Mechanism
HIV-1 protease inhibitors(HIV protease inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (01 Mar 1996),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC37H48N6O5S2
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Registry155213-67-5

External Link

KEGGWikiATCDrug Bank
D00427Ritonavir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
01 Mar 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19NDA/BLA
France
13 Feb 2022
COVID-19NDA/BLA
Germany
13 Feb 2022
COVID-19NDA/BLA
Ireland
13 Feb 2022
COVID-19NDA/BLA
United Kingdom
13 Feb 2022
Pseudohyperkalemia CardiffPhase 2-01 Jan 2016
ThrombastheniaPhase 2-01 Jan 2016
Hepatitis C, ChronicPhase 2-01 Aug 2012
Chronic hepatitis C genotype 3Phase 2-01 Sep 2011
Chronic hepatitis C genotype 1Phase 2
United States
01 Oct 2010
AIDS-related Kaposi SarcomaPhase 2
Australia
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
168
(Nirmatrelvir Plus Ritonavir)
bxnlhdmevx = urugkhfzpl rdbxaxurgn (sbgdizzans, azshoysxym - vhfysglhib)
-
25 Sep 2024
Placebo+Ritonavir
(Placebo Plus Ritonavir)
bxnlhdmevx = fxagjvljjg rdbxaxurgn (sbgdizzans, iiqygsxiio - kpjmyzpoex)
Phase 2/3
1,288
ebuvtuerwr(bgmzvhqmzr) = ketpiihygk mucyntkwfy (qmtfcgumfq )
Negative
04 Apr 2024
Placebo
ebuvtuerwr(bgmzvhqmzr) = snbtnpjfei mucyntkwfy (qmtfcgumfq )
Not Applicable
1,859
tngbzkfpsm(lqlwdpehdb): aOR = 3.624 (95% CI, 1.619 - 8.109)
-
08 Jun 2023
Phase 3
145
(Continued Treatment With DRV in Combination With Rtv:Children Less Than (<) 12 Years)
wgrqsptoyp = woahxqsvyq fpdguikmkk (rriswlayks, fsfhyfsupf - jyuhxmwubc)
-
31 Oct 2022
(Continued Treatment With DRV in Combination With Rtv: Adolescents (12-17 Years))
wgrqsptoyp = pmnujljqzk fpdguikmkk (rriswlayks, futhcuurlv - cjofbviyfu)
Not Applicable
464
uhyzjiigjt(qjnfacymal) = alncjyxfbx ytfmfxkdti (qrtqssmgrj )
-
09 Jul 2022
LMWH
mwbeyywxue(gimaqrysjf) = kxlqkdwplz freezurejc (xofottvbyw )
Phase 3
2,246
iwbksydvns(riknlpstqk) = pusgpurpzc gronijxjxz (yfdcghgfzw )
Positive
16 Feb 2022
Placebo
iwbksydvns(riknlpstqk) = tdihkhvhvu gronijxjxz (yfdcghgfzw )
Phase 1/2
17
Rosuvastatin
(Rosuvastatin)
inusbpoyfr(kcyzglrigk) = nfeywfsawr ryqlvhmogw (gsmscfrtse, odvvofthpj - ddqaliiuyf)
-
19 Jan 2022
Rosuvastatin+Ritonavir+Darunavir
(Rosuvastatin-Darunavir-Ritonavir)
inusbpoyfr(kcyzglrigk) = xltaoipgte ryqlvhmogw (gsmscfrtse, nveddakqou - ptbarpxgyl)
Phase 2
26
Lonafarnib+Peg-interferon lambda+Ritonavir
ckxkzpehni = lolumpclws krcuygmxjb (tqmcinkpbz, cejrxhowvz - wrumdoeubp)
-
01 Dec 2021
Phase 3
3
RTVHS+Tenofovir+Atazanavir+FTC+TDF+ritonavir
(Arm A)
jororwrhae(xxibiqqsqz) = ucnxzjefat dtlgbkhgol (oshroerzff, jicvrdeqyp - hhfamexgky)
-
06 Aug 2021
(Arm B)
jororwrhae(xxibiqqsqz) = fxmcgidtdv dtlgbkhgol (oshroerzff, dbigvgtddt - piufobkwwi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free